RecruitingNCT07227454
Esketamine with usual care for depression and suicidal thoughts in teens
About this title
Read the official source — NCT07227454This study evaluates the safety and effectiveness of Esketamine for people with depression.
Medication studyAges 12–17Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Esketamine for people with depression.
Who could participate?
Listed age limits: 12 years to 17 years.
- Listed locations
- Birmingham and 43 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 8, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 258
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Brazil, Hungary, ...
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT07227454
- Official title
Show the full official title
A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or Behavior
Recruitment & locations
RecruitingBirmingham, United States · New Haven, United States · Washington D.C., United States
40 more locations
- Atlanta, United States
- Evanston, United States
- Baltimore, United States
- Boston, United States
- Rochester, United States
- Chapel Hill, United States
- Cincinnati, United States
- East Providence, United States
- Houston, United States
- Criciúma, Brazil
- Natal, Brazil
- Salvador, Brazil
- São Bernardo do Campo, Brazil
- São Paulo, Brazil
- Budapest, Hungary
- Debrecen, Hungary
- Győr, Hungary
- Szeged, Hungary
- Acireale, Italy
- Cagliari, Italy
- Florence, Italy
- Foggia, Italy
- Genova, Italy
- Merano, Italy
- Naples, Italy
- Sassari, Italy
- Bucharest, Romania
- Cluj-Napoca, Romania
- Sibiu, Romania
- Timișoara, Romania
- Barcelona, Spain
- Esplugues de Llobregat, Spain
- Madrid, Spain
- Manresa, Spain
- Oviedo, Spain
- Pamplona, Spain
- Sabadell, Spain
- Santander, Spain
- New Taipei City, Taiwan
- Taipei, Taiwan
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Esketamine for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Does this study involve medication?
Yes. The study involves medication, including Esketamine and Midazolam.
Who can participate?
Listed age limits: 12 years to 17 years.
Is this study still recruiting?
The registry lists this study as recruiting.
